Last reviewed · How we verify
Ciprofloxacine
At a glance
| Generic name | Ciprofloxacine |
|---|---|
| Sponsor | Poitiers University Hospital |
| Target | DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
- Abdominal abscess
- Acute Moraxella catarrhalis bronchitis
- Acute bacterial bronchitis
- Acute bacterial peritonitis
- Acute bacterial sinusitis
- Acute gonococcal cervicitis
- Acute gonococcal urethritis
- Acute maxillary sinusitis
- Acute osteomyelitis
- Anthrax
- Bacterial Corneal Ulcer Infection
- Bacterial conjunctivitis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial pneumonia
- Bacterial urinary infection
- Chancroid
- Chronic Bacterial Prostatitis
- Citrobacter Urinary Tract Infection
- Complicated Bacterial Peritonitis
- Complicated Bacteroides Peritonitis
Common side effects
Key clinical trials
- A Phase II/III Prospective, Multicenter, Randomized, Controlled Trial Comparing the Safety and Efficacy of Three Clarithromycin-Containing Combination Drug Regimens for the Treatment of Disseminated M (Phase 2)
- A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections (EARLY/Phase 1)
- Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance (N/A)
- Cipro® XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections (Phase 4)
- A Prospective Randomised Controlled Non-inferiority Study to Evaluate the Effectiveness and Safety (APRES) of Non-operative Management in Children With Acute Uncomplicated Appendicitis (NA)
- The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses (NA)
- Safety and Feasibility of a Shigella Sonnei 53G Controlled Human Infection Model in Kenyan Adults: a Dose Finding and Dose Verification Study (Phase 1)
- Antimicrobial Efficacy of Synthetic Versus Herbal Intracanal Medicaments Against Enterococcus Faecalis (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |